ALS investigational therapies DNL343 and fosigotifator fail …
1 day ago · Denali Therapeutics’ DNL343 and fosigotifator, which is being co-developed by Calico Life Sciences and AbbVie, are oral small molecules designed to activate eIF2B, a protein …
Sean M. Healey & AMG Center Announces Update in ALS Platform …
BOSTON – The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital today announced topline results from Regimen F of the HEALEY ALS Platform Trial evaluating f …
Fosigotifator Fails to Meet End Points in HEALEY-ALS Platform Trial
4 days ago · Fosigotifator targets eIF2B, a guanine nucleotide exchange factor that is essential for protein synthesis and a key regulator of the integrated stress response (ISR). In addition to …
Calico Provides Update on Fosigotifator in HEALEY ALS Platform …
5 days ago · The fosigotifator regimen did not meet the study’s primary endpoint of disease progression (a combined analysis of function and mortality) for either the primary or the …
Google's anti-aging company just released 'disappointing' drug …
3 days ago · Fosigotifator targets the integrated stress response (ISR), a cellular mechanism that reduces activity in cells in response to internal or environmental stress. ... STAT news reports . …
Google’s anti-aging company just released ‘disappointing ... - DNyuz
4 days ago · Calico’s fosigotifator was tested for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease that affects nerve cells in the brain and spinal cord and leads to …
ALS drug from Calico, anti-aging company, fails in study - STAT
4 days ago · The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is testing it further and for other conditions.
Rival AbbVie and Denali prospects flunk phase 2/3 ALS tests
3 days ago · The failure of fosigotifator and DNL343 may have implications for Bristol Myers Squibb, which paid Evotec a $20 million option fee to license a eIF2B candidate in 2021.
Calico Life Sciences Announces that Fosigotifator (ABBV-CLS …
Jun 7, 2024 · Calico and AbbVie are currently conducting a Phase 1b /2 trial of fosigotifator to evaluate the safety, tolerability, and pharmacokinetics of fosigotifator in participants diagnosed …
ALS drug by Google's anti-aging subsidiary fails clinical trial
3 days ago · The experimental drug, fosigotifator, was tested as a potential treatment for amyotrophic lateral sclerosis (ALS). This deadly neurodegenerative disease affects the nerve …
- Some results have been removed